These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 3437043)

  • 1. Intravaginal administration of RU 486 in humans and rats: inadequate absorption in humans.
    Heikinheimo O; Croxatto H; Salvatierra AM; Chang CC; Luukkainen T; Lähteenmäki P
    Hum Reprod; 1987 Nov; 2(8):645-8. PubMed ID: 3437043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of the antiprogesterone RU 486 in women during multiple dose administration.
    Heikinheimo O
    J Steroid Biochem; 1989 Jan; 32(1A):21-5. PubMed ID: 2913396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution of RU 486 and its demethylated metabolites in humans.
    Heikinheimo O; Haukkamaa M; Lähteenmäki P
    J Clin Endocrinol Metab; 1989 Feb; 68(2):270-5. PubMed ID: 2918046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the antiprogesterone steroid RU 486 during midluteal phase in normal women.
    Schaison G; George M; Lestrat N; Reinberg A; Baulieu EE
    J Clin Endocrinol Metab; 1985 Sep; 61(3):484-9. PubMed ID: 2991322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486.
    Luukkainen T; Heikinheimo O; Haukkamaa M; Lähteenmäki P
    Fertil Steril; 1988 Jun; 49(6):961-3. PubMed ID: 3371492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma levels of antiprogestin RU 486 following oral administration to non-pregnant and early pregnant women.
    Swahn ML; Wang G; Aedo AR; Cekan SZ; Bygdeman M
    Contraception; 1986 Nov; 34(5):469-81. PubMed ID: 3816231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of oral prostaglandin E2 on uterine contractility and outcome of treatment in women receiving RU 486 (mifepristone) for termination of early pregnancy.
    Swahn ML; Ugocsai G; Bygdeman M; Kovacs L; Belsey EM; Van Look PF
    Hum Reprod; 1989 Jan; 4(1):21-8. PubMed ID: 2651472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiprogesterone steroid RU486. Pharmacokinetics and receptor binding in humans.
    Heikinheimo O
    Acta Obstet Gynecol Scand; 1990; 69(4):357-8. PubMed ID: 2244471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro evaluation and vaginal absorption of metronidazole suppositories in rabbits.
    Ozyazici M; Turgut EH; Taner MS; Köseoglu K; Ertan G
    J Drug Target; 2003 Apr; 11(3):177-85. PubMed ID: 14577974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RU 486: a steroid with antiglucocorticosteroid activity that only disinhibits the human pituitary-adrenal system at a specific time of day.
    Gaillard RC; Riondel A; Muller AF; Herrmann W; Baulieu EE
    Proc Natl Acad Sci U S A; 1984 Jun; 81(12):3879-82. PubMed ID: 6328529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mifegyne (mifepristone), a new antiprogestagen with potential therapeutic use in human fertility control.
    Couzinet B; Schaison G
    Drugs; 1988 Mar; 35(3):187-91. PubMed ID: 3286211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol.
    el-Refaey H; Rajasekar D; Abdalla M; Calder L; Templeton A
    N Engl J Med; 1995 Apr; 332(15):983-7. PubMed ID: 7885426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levels of the antiprogestin RU 486 and its metabolites in human blood and follicular fluid following oral administration of a single dose.
    Cekan S; Aedo AR; Segerstéen E; Van Look P; Messinis I; Templeton A
    Hum Reprod; 1989 Feb; 4(2):131-5. PubMed ID: 2918065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regression of uterine leiomyomata in response to the antiprogesterone RU 486.
    Murphy AA; Kettel LM; Morales AJ; Roberts VJ; Yen SS
    J Clin Endocrinol Metab; 1993 Feb; 76(2):513-7. PubMed ID: 8432797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of chronic treatment with the glucocorticoid antagonist RU 486 in man: toxicity, immunological, and hormonal aspects.
    Laue L; Lotze MT; Chrousos GP; Barnes K; Loriaux DL; Fleisher TA
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1474-80. PubMed ID: 2172280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of the progesterone antagonist 17 beta-hydroxy-11 beta-(4-dimethylaminophenyl)-17 alpha-(1-propynyl) estra-4,9-dien-3-one in the rabbit.
    Wang G; Aedo AR; Cekan SZ
    Arzneimittelforschung; 1986 Jun; 36(6):936-8. PubMed ID: 3741527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transplacental passage of mifepristone and its influence on maternal and fetal steroid concentrations in the second trimester of pregnancy.
    Hill NC; Selinger M; Ferguson J; MacKenzie IZ
    Hum Reprod; 1991 Mar; 6(3):458-62. PubMed ID: 1955558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical use of RU 486: control of the menstrual cycle and effect on the hypophyseal-adrenal axis].
    Gaillard RC; Herrmann W
    Ann Endocrinol (Paris); 1983; 44(5):345-6. PubMed ID: 6675522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Abortion induced by RU 486: importance of its combination with a prostaglandin derivative].
    Dubois C; Ulmann A; Aubeny E; Elia D; Jourdan MC; Van den Bosch MC; Leton M; Baulieu EE
    C R Acad Sci III; 1988; 306(2):57-61. PubMed ID: 3126988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Termination of pregnancy at 9-13 weeks' amenorrhoea with mifepristone and misoprostol.
    Ashok PW; Flett GM; Templeton A
    Lancet; 1998 Aug; 352(9127):542-3. PubMed ID: 9716062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.